HC Wainwright Comments on TG Therapeutics Q1 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – HC Wainwright issued their Q1 2025 earnings per share estimates for shares of TG Therapeutics in a research report issued on Tuesday, March 4th. HC Wainwright analyst E. White forecasts that the biopharmaceutical company will post earnings per share of $0.28 for the quarter. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q2 2025 earnings at $0.32 EPS, Q3 2025 earnings at $0.37 EPS and Q4 2025 earnings at $0.42 EPS.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million.

A number of other research firms also recently issued reports on TGTX. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Stock Performance

Shares of TGTX opened at $38.44 on Thursday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a 50-day moving average of $30.95 and a 200-day moving average of $28.43. The company has a market cap of $5.98 billion, a PE ratio of -384.36 and a beta of 2.30. TG Therapeutics has a one year low of $12.93 and a one year high of $38.58.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds have recently modified their holdings of TGTX. Vermillion Wealth Management Inc. bought a new position in shares of TG Therapeutics during the 4th quarter worth approximately $30,000. Quadrant Capital Group LLC raised its holdings in shares of TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 975 shares during the period. Blue Trust Inc. raised its holdings in shares of TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 371 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,594 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in shares of TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,737 shares during the period. Institutional investors own 58.58% of the company’s stock.

Insiders Place Their Bets

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.